Related Experiment Videos
Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited
E Kebebew1, P A Treseler, P H Ituarte
1Department of Surgery, S343, University of California, San Francisco, School of Medicine, 513 Parnassus Street, San Francisco, California 94143-0470, USA. tron@itsa.ucsf.edu
World Journal of Surgery
|May 23, 2001
Summary
Chronic lymphocytic thyroiditis (CLT) often co-occurs with papillary thyroid cancer (PTC), and while it correlates with improved prognosis, it is not an independent factor for recurrence or metastasis.
Area of Science:
- Endocrinology
- Oncology
- Immunology
Background:
- The interplay between chronic lymphocytic thyroiditis (CLT) and papillary thyroid cancer (PTC) behavior is not fully understood.
- Previous studies suggest a potential link between CLT, tumor-infiltrating lymphocytes (TILs), and improved outcomes in PTC patients.
- A tumor immune response in PTC has been hypothesized based on these observations.
Purpose of the Study:
- To determine the frequency of CLT in PTC patients.
- To evaluate the prognostic significance of CLT in PTC.
- To investigate the association between TILs and CLT in PTC.
Main Methods:
- A retrospective study of 136 PTC patients who underwent thyroidectomy between 1986 and 1996.
- Histopathological assessment of lymphocytic infiltration (CLT and TILs) by blinded observers.
- Univariate and multivariate analyses to identify prognostic factors.
Main Results:
- Thirty percent of PTC patients had coexisting CLT.
- TILs were predominantly found in patients with CLT (82.5% vs. 5% without CLT).
- CLT was associated with younger age, female gender, and multicentric tumors, and correlated with an improved prognosis but was not an independent prognostic factor.
Conclusions:
- CLT frequently coexists with PTC, and TILs are primarily associated with CLT.
- While CLT correlates with an improved prognosis in PTC, it does not independently predict lower recurrence or metastasis.
- Further research may clarify the precise role of the immune response in PTC progression.